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CYSTIC FIBROSIS
Fatime Sylla
Overview
Cystic fibrosis (CF) is one of the lethal  
autosomal recessive disease that “ 
causes persistent lung infections and 
limits the ability to breathe overtime” 
(Cystic Fibrosis foundation, 2018).
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Pathophysiology 
CF affects the cells that produce 
mucus, sweat and digestive juices. 
These secreted fluids are normally thin 
and slippery. But in people with CF, a 
defective gene causes the secretions to 
become  sticky and thick. Instead of 
acting as a lubricant, the secretions plug 
up tubes, ducts and passageways 
especially in the lungs and pancreas 
(Mayo Clinic, 2016).
CF is caused by defects in the cystic 
fibrosis gene, which codes for a protein 
transmembrane conductance regulator 
(CFTR) that functions as a chloride 
channel and is regulated by cyclic 
adenosine monophosphate (cAMP). 
Mutations in the CFTR gene result in 
abnormalities of cAMP-regulated 
chloride transport across epithelial cells
Cystic fibrosis is a complex disease 
that requires the dedication of healthcare 
providers that focus on providing 
specialized care and disease 
management. CF patients live depend on 
combination therapies that help loosen 
and get rid of the thick mucus that can 
build up in the lungs, open the airways 
or thin the mucus through inhaled 
medicines, and improve the absorption 
of vital nutrients by providing pancreatic 
enzymes supplement capsules (Cystic 
Fibrosis Foundation, 2018, treatment). 
However, as Garner, Gray, self and 
Wagener (2017) outlined, it is vital for 
patients to fully commit to their 
treatment to ensure positive outcomes 
by creating specialized individual plans. 
Care team must utilize strategies that 
increase communication with patients to 
“establish and document realistic, 
meaningful, and achievable goals; and 
ensure follow-up on progress and 
barriers to progress” (p.766). 
Finally, despite tremendous 
achievements in the fight for the cure of 
CF, too many lives are still being lost. 
And the more one understands the 
underlying mechanism of CF, the better 
equipped one is to handle this illness. In 
this perspective, genetic research with 
precision medicine offers the key to not 
only finding treatments that improve 
quality of life of CF patients but also in 
the fight of finding the cure for this 
terrible disease.
Facts about Cystic Fibrosis
✓ Life Expectancy of people with 
CF is mid- to late 30s
✓ More than 30, 000 of people 
live with CF ( 70,000 
worldwide) 
✓ Approximately, 1,000 new 
cases are diagnosed each year
✓ More than 75 % of people with 
CF are diagnosed  by age 2
✓ More than half of CF population 
is 18 and older (Cystic Fibrosis 
Foundation, 2018).
✓ Lungs disease are 80% of CF 
mortality (Cutting, 2015, p.45)
Risk factors
✓ Race: commonly in white of 
Northern Europe ( but occurs 
in all races and ethnicities)
✓ Males and females
✓ More than 10 million 
Americans are carriers of a 
faulty CF gene (NIH, 2018).
✓ Family history: Inherited 
disorder, both parents must 
have a least one copy of the 
defective gene for the child to 
have the disease or  (Cystic 
Fibrosis Foundation, 2018)
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Conclusion 
In addition to clinical symptoms,  doctors diagnose CF based on multiple tests 
including:
✓ Newborn screening (blood sample is checked for higher than normal levels of a 
chemical (immunoreactive trypsinogen, or IRT) released by the pancreas)
✓ Sweat test  
✓ Other tests:
▪ Genetic tests ( for type of CFTR defect)
▪ Chest x-ray
▪ Sinus x-ray
▪ Lung functions test
▪ Sputum culture
✓ Prenatal screening
✓ CF carrier testing ( detect faulty genes 9 out of 10 cases) ( NHLBI, 2018, 
diagnosis).
Table 1
Summary of different classes of CFTR  mutations
“The signs and symptoms of cystic 
fibrosis (CF) vary from person to person 
(..)” (NHLBI, 2018).
Respiratory symptoms
✓ Persistent cough that produces 
thick mucus
✓ Wheezing
✓ Breathlessness
✓ Exercise intolerance
✓ Repeated lung infections
✓ Inflamed nasal passage or stuffy 
nose (Mayo clinic, 2016)
Understand Cystic Fibrosis
signs, symptoms and complications
Symptoms vary over time and as 
disease gets worse, they  are more severe 
(NHLBI, 2018).
Digestive symptoms
✓ Foul-smelling greasy stools
✓ Poor weight gain and growth
✓ Intestinal blockage, particularly in 
newborns
✓ Severe constipation
✓ Rectal prolapse (Mayo Clinic, 2016)
Diagnosis 
There is no cure. The goal of 
treatment include preventing and 
controlling lungs infection, loosening and 
removing thick an sticky mucus from 
lungs, preventing or treating  blockage in 
the intestines, providing enough 
nutrition an preventing dehydration.        
This requires a multidisciplinary 
approach that involves a medical team of 
nurses, physical therapy , dietitians and 
social workers. Also, depending on the 
severity of symptoms, the CF treatment 
may requires long stay at he hospital 
(NHLBI, 2018, Treatment). 
Type of treatments 
✓ Chest physical therapy  that is called 
clapping or percussion involving 
pounding  chest and back over and 
over with hands or devices
✓ Aerobic Exercise
✓ Treatment for advanced lung 
disease ( oxygen therapy or 
transplant) 
✓ Pulmonary rehabilitation  that 
include exercise training, , 
nutritional counseling, education on  
lung disease or condition and how 
to manage it, energy-conserving 
techniques, breathing strategies, 
psychological counseling and/or 
group support
✓ Nutritional therapy with a well-
balanced diet that's rich in calories, 
fat, and protein (  NHLBI, 2018) 
✓ Traditional medicines:
• Antimicrobial agents
• Anti-inflammatory 
agents
• Bronchodilators
• Oral pancreatic 
enzymes (Mayo clinic, 
2016, Medications).
✓ Precision medicines such as   gene 
therapies for improving 
Transmembrane Regulator (CFRT) 
Function (e.g. Ivacaftor) (Murphy & 
Caraher, 2016, p.2)  or gene therapy 
for restoration of normal CFTR 
function (Murphy & Caraher, 2016, 
p.9)
✓ Treatment of common 
complications such as diabetes and 
Osteoporosis (NHLBI, 2018).
on mucosal surfaces (Sharma, 2018).          
Almost 2000 disease causing
mutations have been identified in 
people with cystic fibrosis to date, but  
most of the cases can be classified into 
six classes according to the genetic 
mutations as shown in  table 1 (Brodie, 
Haq, Roberts and Elborn, 2015, p.2).    
The variability of mutations are 
linked to the severity of the disease.     
However,  two individuals with the 
same CFTR genotype may follow a 
different natural history and trajectory 
of their lung disease due to 
environmental, microbiological and 
socioeconomic factors, as well as 
adherence with treatment and 
modifier genes (Brodie et al., 2015).
Mutation Class Nature of defect Functional consequence
I CFTR protein synthesis Reduced CFTR protein 
expression
II CFTR protein processing Misfolded CFTR not 
transported at to cell surface
III CFTR channel gating Reduced/lack of CFTR 
channel opening
IV CFTR channel conductance Misshaped CFTR pore 
restricts Cl− movement
V Reduced CFTR protein 
production
Very low levels of CFTR 
protein
VI CFTR protein turnover at cell 
surface
Functional but unstable CFTR 
protein at cell surface
Note. Adapted from “Targeted Therapies to Improve CFRT Function in Cystic fibrosis” by M. Brodlie, 
I. J. Hag, K. Roberts and J. S. Elborn, 2015, Genome Medicine, p. 2.
